Ignite Creation Date:
2024-05-06 @ 1:05 PM
Last Modification Date:
2024-10-26 @ 1:08 PM
Study NCT ID:
NCT03927443
Status:
WITHDRAWN
Last Update Posted:
2021-11-19
First Post:
2019-04-22
Brief Title:
A Comparative Study of SPARCs SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
Sponsor:
Sun Pharmaceutical Industries Limited
Organization:
Sun Pharmaceutical Industries Limited
Study Overview
Official Title:
A Multi-Center Evaluator -Masked Randomized Parallel Group Active Controlled Comparative Study of SPARCs SDP-133 Once Daily Compared With Lumigan 001 Bimatoprost Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status:
WITHDRAWN
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsors decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of once daily dosing with SPARCs novel ophthalmic formulation of bimatoprost compared with Lumigan 001 in subjects with open-angle glaucoma or ocular hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None